eMedicine Specialties > Psychiatry > Adult

Schizophrenia: Differential Diagnoses & Workup

Author: Frances R Frankenburg, MD, Associate Professor, Department of Psychiatry, Boston University School of Medicine; Chief of Inpatient Psychiatry and Consulting Psychiatrist, Edith Nourse Rogers Memorial Veterans Administration Medical Center; Associate Psychiatrist, McLean Hospital
Contributor Information and Disclosures

Updated: Sep 10, 2009

Differential Diagnoses

Addison Disease
Hyperthyroidism
ALA Dehydratase Deficiency Porphyria
Hypocalcemia
Alcohol-Related Psychosis
Hypoglycemia
Behcet Disease
Hypokalemia
Bipolar Affective Disorder
Hypomagnesemia
Brain Abscess
Hyponatremia
Brief Psychotic Disorder
Hypoparathyroidism
Churg-Strauss Syndrome
Hypothyroidism
Cocaine-Related Psychiatric Disorders
Lung Cancer, Oat Cell (Small Cell)
Cytomegalovirus
Mental Disorders Secondary to General Medical Conditions
Delusional Disorder
Paraneoplastic Syndromes
Depression
Phencyclidine (PCP)-Related Psychiatric Disorders
Encephalopathy, Dialysis
Porphyria, Acute Intermittent
Encephalopathy, Hepatic
Schizoaffective Disorder
Encephalopathy, Hypertensive
Schizophreniform Disorder
Encephalopathy, Uremic
Shared Psychotic Disorder
Folic Acid Deficiency
Substance-Induced Mood Disorder With Depressive Features
Head Trauma
Systemic Lupus Erythematosus
Huntington Disease Dementia
Wernicke-Korsakoff Syndrome
Hypercalcemia
Wilson Disease
Hyperparathyroidism

Other Problems to Be Considered

Other psychiatric illnesses

  • Bipolar disorder: Schizophrenia and bipolar affective disorder (manic-depressive illness) may be difficult to distinguish from each other. Patients with manic-depressive illness predominantly have disturbances in their affect or mood. Psychotic symptoms may be prominent during a mania or depression. In classic manic-depressive illness, the psychotic symptoms are congruent with mania or depression, and the person has periods of euthymia (normal mood) with no psychotic symptoms between the episodes. However, some patients have, in the absence of depression or mania, periods of psychotic symptoms. The diagnosis of schizoaffective disorder is used in these cases.
  • Delusional disorder: In this disorder, the person has a variety of paranoid beliefs, but these beliefs are not bizarre and are not accompanied by any other symptoms of schizophrenia. For example, a person who is functioning well at work but becomes unreasonably convinced that his or her spouse is having an affair has a delusional disorder rather than schizophrenia.
  • Schizotypal personality disorder: In this personality disorder, a pervasive pattern of discomfort in close relationships with others exists, and odd thoughts and behaviors occur. The oddness in this disorder is not as extreme as that observed in schizophrenia.
  • Schizoid personality disorder: In this personality disorder, the person has difficulty and lack of interest in forming close relationships with others and prefers solitary activities. No other symptoms of schizophrenia are present.
  • Paranoid personality disorder: In this personality disorder, the person is distrustful and suspicious of others. No actual delusions or other symptoms of schizophrenia are present.

Medical illnesses

  • Anatomic lesions
    • Brain tumors: Patients with these conditions rarely initially present with psychosis. But brain tumors have no predictable set of symptoms. Because brain tumors can be treated and can be lethal, it is important to consider brain imaging studies for every person with a new onset of a psychotic illness or, perhaps, a marked change in symptomatology.
    • Idiopathic calcification of the basal ganglia: This is a rare disorder in which patients may present early in adulthood with psychosis.14
    • Intracranial bleeds: Patients who report head trauma or who, for whatever reason, are not able to provide a clear history, probably should have brain imaging performed to rule out subdural hematomas, which can manifest as changes in mental status.
Metabolic illnesses
  • Wilson disease: This illness, also known as hepatolenticular degeneration, is a disorder of the metabolism of copper. It is an autosomal recessive illness, the gene for which has been located on chromosome 13. The first symptoms are often vague changes in behavior during adolescence, followed by the appearance of odd movements. The diagnosis can be indicated by the laboratory findings of increased urinary copper levels and low levels of serum copper and ceruloplasmin or the detection of Kayser-Fleischer rings (copper deposits around the cornea) with or without a slit-lamp examination. The diagnosis is usually confirmed by finding increased hepatic copper at biopsy.

    The diagnosis can be quite difficult to make because not all patients with Wilson disease have low serum ceruloplasmin or Kayser-Fleischer rings, the 2 findings most commonly associated with this disorder. Because the treatment of this disease is also difficult, some experts recommend liver biopsy so that a tissue diagnosis may be made before chelating therapy is started. This is an important diagnosis to make because of the existence of a very specific treatment.
  • Porphyria: Patients with this disorder of heme biosynthesis can present with psychiatric symptoms. There may be a family history of psychosis. The psychiatric symptoms may be associated with electrolyte changes, peripheral neuropathy, and episodic severe abdominal pain. Abnormally high levels of porphyrins in 24-hour urine collections confirm the diagnosis.
  • Other metabolic disturbances: Patients with hypoxemia or electrolyte disturbances may present with confusion and psychotic symptoms. A hypoglycemic person is particularly likely to be confused, irritable, and mistaken for a person who is psychotic.
  • Delirium: Delirium, from whatever cause (eg, metabolic or endocrine disorders), is an important condition to consider, especially in the elderly or hospitalized person.

Endocrine disorders

  • Thyroid dysfunction: Severe hypothyroidism or hyperthyroidism can be associated with psychotic symptoms. Hypothyroidism is usually associated with depression. If the depression is severe, associated psychotic symptoms may exist. A hyperthyroid person is typically depressed, anxious and irritable. In infrequent cases, the presentation may be confused with schizophrenia.
  • Adrenal dysfunction: Mental status changes may occur in hypoadrenalism (Addison disease) and hyperadrenalism (Cushing disease). Artificially induced hyperadrenalism, as when patients are treated with high doses of steroids for medical illnesses, is associated with changes in mental status.
  • Parathyroid dysfunction: Hypoparathyroidism or hyperparathyroidism with changes in calcium can on occasion be associated with vague mental status changes.
Infectious illnesses

Many infectious illnesses, such as influenza, Lyme disease, hepatitis C, and any of the encephalitides (particularly those caused by the herpes viruses), can cause mental status changes such as depression, anxiety, irritability, or psychosis. Elderly people with pneumonias or urinary tract infections may become confused or frankly psychotic.

The infectious illnesses of particular interest are the following:
  • Neurosyphilis: This can be divided into meningovascular syphilis, tabes dorsalis, or general paresis. Patients with general paresis may present with behavioral changes, psychosis or dementia. The diagnosis can be suggested by a history of exposure, personality changes, and pupillary changes such as the Argyll Robertson pupil. The Venereal Disease Research Laboratory (VDRL) and rapid plasma reagin (RPR) tests are nontreponemal tests that use antigens to detect antibodies to Treponema pallidum. Antibodies decline during the disease, so these tests have a high false-negative rate. If neurosyphilis is strongly suspected, the more specific treponemal tests, such as the fluorescent-treponemal antibody absorption test (FTA-ABS) can be useful.
  • HIV: HIV penetrates the blood-brain barrier early in the course of HIV infection, so HIV infection is associated with a number of mental status changes, particularly dementia or other neuropsychological impairment. Patients with HIV are at risk for opportunistic infections, such as neurosyphilis, toxoplasmosis, cryptococcal meningitis, progressive multifocal leukoencephalopathy, cytomegalovirus encephalopathy, and tuberculous meningitis, all of which can lead to altered mentation. Persons infected with HIV are also at risk for primary central nervous system lymphoma and may present with vague symptoms such as confusion and memory loss. Many drugs used to treat HIV may cause mental status changes. Finally, persons infected with HIV are at risk for nutritional deficiencies that also contribute to mental status changes.
  • Cerebral abscess: Patients with cerebral abscesses rarely initially present with psychosis, but brain imaging should be considered to rule out this treatable possibility. Immunosuppressed or persons living in or traveling in underdeveloped countries are particularly at risk.
  • Creutzfeldt-Jakob disease: Prions cause the rare Creutzfeldt-Jakob disease (CJD), one of the transmissible spongiform encephalopathies. The disease usually occurs in people older than 50 years and is marked by rapid deterioration, dementia, abnormal EEG complexes, and myoclonic jerks. A variant of this illness, vCJD, is the human form of mad cow disease, bovine spongiform encephalopathy. Fewer than 200 cases of vCJD have occurred worldwide, and only 2 cases have occurred in the United States (as of 2003). Unlike CJD, this disease seems to affect people aged 20-40 years. The illness is much longer lasting than CJD and begins with behavioral changes. In several cases, the person was diagnosed with schizophrenia before the diagnosis of vCJD was made.
Other illnesses
  • Multiple sclerosis: This illness is notoriously difficult to diagnose in its early stages. The physical symptoms can be overlooked, and psychological symptoms may occasionally be the presenting feature.
  • Huntington disease: In this neurodegenerative disorder, neuronal loss throughout the brain occurs, especially in the striatum. This is an autosomal dominant disorder, the gene for which has been located on chromosome 4. Family history is essential to making the diagnosis, but it can be misleading. The occurrence of choreoathetoid movements well before exposure to antipsychotic agents is suggestive of Huntington disease. About three fourths of patients with Huntington disease initially present with psychiatric symptoms, and most need inpatient psychiatric care at some point in their illness.
  • Dementia with Lewy bodies: Patients with the second most common type of dementia (after Alzheimer disease) present with fluctuating mental status and prominent psychiatric symptoms, including depression and visual hallucinations. This is an important disorder to diagnose because these patients are reported to do poorly when treated with antipsychotic drugs.
  • Lipid storage disorders: These disorders include metachromatic leukodystrophy, adrenoleukodystrophy, GM2 gangliosidosis, and ceroid lipofuscinosis. These illnesses usually occur in childhood but may occasionally come to medical attention during adolescence. Patients may present with psychiatric symptoms such as cognitive deterioration and changes in personality. Patients may be diagnosed with schizophrenia until the neurologic symptoms of these illnesses become more prominent.15
  • Paraneoplastic neurologic syndromes: Malignancies can occasionally lead to dramatic mental status changes early in their course and before they have been diagnosed or metastasized to the brain. The etiology is not clear. Various syndromes have been described, including subacute cerebellar degeneration, encephalopathy with brainstem involvement, diffuse encephalopathies with mental symptoms, and limbic encephalopathy. The carcinoma is typically a bronchial oat-cell carcinoma.
  • Seizure disorder: Occasionally, patients with a seizure disorder, especially temporal lobe epilepsy, may display odd behavior before, during, or after a seizure. Aura and ictal symptoms can include hallucinations, disturbances of memory, or affective and cognitive changes. Ictal and postictal phenomena can include motor abnormalities, which can be quite complex.
  • Systemic lupus erythematosus: Patients with this connective tissue disease, typically young women, present with unexplained fever and/or joint pain in association with psychiatric symptoms, such as psychosis or cognitive deficit. The diagnosis can be suggested by the physical findings of malar flush and the laboratory findings of anemia, renal dysfunction, and elevated erythrocyte sedimentation rate (ESR) and, most specifically, antinuclear antibody (ANA) levels.
  • Vasculitis: In cases of systemic vasculitides, such as polyarteritis nodosa, Churg-Strauss syndrome, Wegener granulomatosis, or Behcet disease, patients may present with personality changes. Other symptoms such as weight loss and fever usually occur. MRI scans show characteristic lesions of vasculitis.
Other conditions
  • Heavy metal toxicity: People exposed to heavy metals, usually in the course of their work, may develop changes in their personality, cognitions, or mood. Heavy metals sometimes contaminate herbal medications.
  • Medication: Many medications have been associated with mental status changes. The more commonly implicated ones are corticosteroids (psychosis or mania); levodopa (hallucinations or insomnia); antidepressants (mania); interferon-alpha (depression); and beta-blockers, including beta-blockers in eye drops (depression).
  • Substance abuse (eg, alcohol, cocaine, opiates, psychostimulants, hallucinogens): Disturbed perceptions, thought, mood, and behavior associated with substance abuse are not uncommon. Anabolic steroids used by body builders can lead to psychotic symptoms.16
  • Anticholinergic medications can lead to delirium and can be abused.
Vitamin deficiency
  • Thiamine deficiency: People who rely on alcohol for calories or patients with advanced malignancies or malabsorption syndromes may become deficient in this vitamin. Acute and severe depletion of this vitamin can lead to Wernicke encephalopathy, marked by oculomotor disturbances, ataxia, and confabulation. If untreated, Korsakoff psychosis may develop. Wernicke encephalopathy is a common cause of chronic cognitive impairment in people with alcoholism, and it is underdiagnosed.17
  • Vitamin B-12 and/or folate deficiency: Patients with either deficiency may present with depression or dementia or, very rarely, delusional thinking.

Workup

Laboratory Studies

No characteristic laboratory results are found in schizophrenia. The following blood work should be performed on all patients, at the beginning of the illness and periodically afterwards:

  • Complete blood count
  • Liver, thyroid, and renal function tests
  • Electrolyte, glucose, B12, folate, and calcium level
  • If the patient's history provides any reason for suspicion, check HIV; RPR; ceruloplasmin; ANA; urine for culture and sensitivity and/or drugs of abuse; a.m. cortisol, and 24-hour urine collections for porphyrins, copper, or heavy metals.
  • If the patient is a woman of childbearing age, a pregnancy test is important.
  • If a strong suspicion of neurosyphilis exists, specific treponemal tests may be helpful.

Imaging Studies

  • Brain imaging is indicated to rule out subdural hematomas, vasculitis, cerebral abscesses, and tumors.
  • A chest x-ray should be done if pulmonary illness or occult malignancy is suspected.

Other Tests

  • Neuropsychological testing in patients with schizophrenia often shows poor information processing, impaired memory, difficulty in abstraction and recognizing social cues, and easy distractibility. Determination of the patient's cognitive weaknesses and strengths can be helpful in treatment planning.
  • If indicated, an electroencephalogram can be useful.
  • Dexamethasone suppression test and adrenocorticotropic hormone (ACTH) stimulation tests are used to establish the diagnosis of hypercortisolism and hypocortisolism, respectively.

Procedures

  • If a strong suspicion of Wilson disease exists, consider a liver biopsy (or multiple biopsies) to confirm the diagnosis.

More on Schizophrenia

Overview: Schizophrenia
Differential Diagnoses & Workup: Schizophrenia
Treatment & Medication: Schizophrenia
Follow-up: Schizophrenia
References
Further Reading

References

  1. Wright IC, Rabe-Hesketh S, Woodruff PW, et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. Jan 2000;157(1):16-25. [Medline].

  2. Sigmundsson T, Suckling J, Maier M, et al. Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry. Feb 2001;158(2):234-43. [Medline].

  3. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry. Jan-Feb 1996;3(5):241-53. [Medline].

  4. Hyde TM, Deep-Soboslay A, Iglesias B, et al. Enuresis as a premorbid developmental marker of schizophrenia. Brain. Sep 2008;131:2489-98. [Medline].

  5. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. Nov 19 1994;344(8934):1398-402. [Medline].

  6. Ho BC, Andreasen NC. Long delays in seeking treatment for schizophrenia. Lancet. Mar 24 2001;357(9260):898-900. [Medline].

  7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th ed. Washington, DC: American Psychiatric Press; 2000.

  8. Kety SS, Wender PH, Jacobsen B, et al. Mental illness in the biological and adoptive relatives of schizophrenic adoptees. Replication of the Copenhagen Study in the rest of Denmark. Arch Gen Psychiatry. Jun 1994;51(6):442-55. [Medline].

  9. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. May 15 2005;57(10):1117-27. [Medline].

  10. Shifman S, Johannesson M, Bronstein M, et al. Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genet. Feb 2008;4(2):e28. [Medline].

  11. Wratten NS, Memoli H, Huang Y, Dulencin AM, Matteson PG, Cornacchia MA, et al. Identification of a schizophrenia-associated functional noncoding variant in NOS1AP. Am J Psychiatry. April/2009;166:434-41. [Medline].

  12. Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M, et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry. Aug 2004;61 (8):774-80. [Medline].

  13. Torrey EF, Bowler AE, Rawlings R, Terrazas A. Seasonality of schizophrenia and stillbirths. Schizophr Bull. 1993;19(3):557-62. [Medline].

  14. Cummings JL, Gosenfeld LF, Houlihan JP, McCaffrey T. Neuropsychiatric disturbances associated with idiopathic calcification of the basal ganglia. Biol Psychiatry. May 1983;18(5):591-601. [Medline].

  15. Rosebush PI, MacQueen GM, Clarke JT, et al. Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues. J Clin Psychiatry. Aug 1995;56(8):347-53. [Medline].

  16. Pope HG Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry. May 1994;51(5):375-82. [Medline].

  17. Reuler JB, Girard DE, Cooney TG. Current concepts. Wernicke's encephalopathy. N Engl J Med. Apr 18 1985;312(16):1035-9. [Medline].

  18. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. Nov 2001;158(11):1774-82. [Medline].

  19. Vieweg WV. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry. October/2003;5:205-215. [Medline].

  20. Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet. Apr 1 2000;355(9210):1155-6. [Medline].

  21. Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic drugs and venous thromboembolism. Lancet. Jul 15 2000;356(9225):252. [Medline].

  22. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. Suppl 1 2007;68:20-7. [Medline].

  23. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med. Mar 14 1991;324(11):746-54. [Medline].

  24. [Best Evidence] Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. Jan 21 2009;CD000059. [Medline].

  25. Kern RS, Glynn SM, Horan WP, Marder SR. Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull. Mar 2009;35(2):347-61. [Medline].

  26. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. May 2006;163:790-9. [Medline].

  27. Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. J Affect Disord. Sep 1982;4(3):173-93. [Medline].

  28. Fazel S, Langstrom N, Hjern A, Grann M, Lichtenstein P. Schizophrenia, substance abuse, and violent crime. JAMA. May 20 2009;301(19):2016-23. [Medline].

  29. Salokangas RK. Medical problems in schizophrenia patients living in the community (alternative facilities). Curr Opin Psychiatry. Jul/2007;20:402-5. [Medline].

  30. Lamb HR, Bachrach LL. Some perspectives on deinstitutionalization. Psychiatr Serv. Aug 2001;52(8):1039-45. [Medline].

Keywords

schizophrenia, schizophrenia symptoms, schizophrenia test, childhood schizophrenia, schizophrenic, signs of schizophrenia, dementia praecox, auditory hallucinations, impaired information processing, delusions, disorganized speech, disorganized behavior, psychiatric disorders, thought disturbances, distorted thinking, mental illness, psychosis, mental disorder, delusions, depression, mania, manic depressive, major depressive disorder, mood disorder, bipolar disorder

Contributor Information and Disclosures

Author

Frances R Frankenburg, MD, Associate Professor, Department of Psychiatry, Boston University School of Medicine; Chief of Inpatient Psychiatry and Consulting Psychiatrist, Edith Nourse Rogers Memorial Veterans Administration Medical Center; Associate Psychiatrist, McLean Hospital
Frances R Frankenburg, MD is a member of the following medical societies: Alpha Omega Alpha, American Psychiatric Association, and International Society for the Study of Personality Disorders
Disclosure: Nothing to disclose.

Medical Editor

Ronald C Albucher, MD, Chief Medical Officer, Westside Community Services; Consulting Staff, California Pacific Medical Center
Ronald C Albucher, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Eduardo Dunayevich, MD, Adjunct Assistant Professor, Department of Psychiatry, University of Cincinnati; Clinical Research Physician, Neuroscience, Lilly Research Laboratories
Eduardo Dunayevich, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: Nothing to disclose.

CME Editor

Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin
Harold H Harsch, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: lilly Honoraria Speaking and teaching; Forest Labs Honoraria Speaking and teaching; AstraZeneca Honoraria Speaking and teaching; Pfizer Grant/research funds Speaking and teaching; Northstar Grant/research funds Research; Novartis Grant/research funds research; Pfizer  Speaking and teaching; Sanofi-avetis Grant/research funds research; Otsuke Grant/research funds reseach; GlaxoSmithKline Grant/research funds research

Chief Editor

Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA
Stephen Soreff, MD is a member of the following medical societies: American College of Mental Health Administration and American Psychosomatic Society
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.